• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Unlearn Raises $50M to Accelerate AI-Powered Clinical Trials with Digital Twins

by Fred Pennic 02/08/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Unlearn®, a leading AI company using digital twins to revolutionize clinical trials, announced today a $50M Series C funding round led by Altimeter Capital. This investment, bringing Unlearn’s total funding to over $130M, will fuel its mission to eliminate trial and error in medicine through faster, smaller, and more ethical clinical trials.

– Unlearn collaborates with pharmaceutical companies, biotechs, and academic institutions to optimize and streamline clinical trials. Their innovative technology holds immense potential to accelerate medical advancements and improve patient outcomes worldwide.

AI-Powered Clinical Trials with Digital Twins

Founded in 2017, Unlearn has consistently pushed the boundaries of AI in clinical research. Their innovative approach uses digital twins, AI-generated models that predict individual patient health outcomes under different treatment scenarios. This allows for TwinRCTs™, highly efficient trials with smaller control groups, enabling more patients to receive active treatment and accelerating the development of life-saving therapies.

Addressing Critical Industry Challenges

The clinical research industry faces challenges like slow enrollment, lengthy timelines, and patient reluctance to participate in placebo-controlled trials. Unlearn’s digital twins offer a solution, potentially:

  • Reducing trial duration: Bringing new drugs to market faster means faster access to potentially life-changing therapies.
  • Increasing patient access: More patients receive active treatments, reducing the ethical concerns of traditional trials.
  • Streamlining processes: Smaller control groups and efficient data analysis lead to faster and more cost-effective trials.

Regulatory Backing for Innovation

Unlearn understands the importance of regulatory compliance. They’ve partnered with experts since their inception and secured qualification from the European Medicines Agency and agreement from the US FDA, ensuring their methodology aligns with current regulations.

“Pharmaceutical companies are spending over $100 billion dollars a year on clinical research, yet the industry remains skeptical about new technology that has the power to truly transform research,” said Charles Fisher, Ph.D., founder and CEO of Unlearn. “Breaking down these barriers and proving the value of digital twin technology continues to be a main driver for us at Unlearn. And, this round of financing will allow us to not only grow our team but also expand our capabilities into more therapeutic areas to build awareness and prove the value.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Clinical Trials, digital twin technology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |